Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Did Medtronic (NYSE:MDT) Lead a 3.9% Medtech Rally?

Medtronic (NYSE:MDT) gained 3.9% in the October 12, 2026 session, according to published market data, and four peers also rose. Zimmer Biomet (NYSE:ZBH) added 3.4%. Insulet (NASDAQ:PODD) added 3.3%. GE HealthCare Technologies (NASDAQ:GEHC) gained 3.0%. Becton Dickinson (NYSE:BDX) gained 2.8%, so the five names …

Vinay Lochav | 13 October 2026

Why Does UnitedHealth (NYSE:UNH) Face a USD 4.12 EPS Test Today?

Per published estimates, UnitedHealth Group (NYSE:UNH) is expected to report earnings per share of USD 4.12 on revenue of about USD 111.3 billion for the quarter. Both figures appear in two separate estimate sets, which makes them more reliable than most single figures. Consensus …

Vinay Lochav | 13 October 2026

Why Do Johnson & Johnson (NYSE:JNJ) Results Test a USD 2.53 Bar?

Per published estimates, Johnson & Johnson (NYSE:JNJ) is expected to post earnings per share of USD 2.53 to USD 2.54 on revenue of about USD 25.4 billion. The one-cent gap reflects the use of different providers, so the article uses the range. The company …

Vinay Lochav | 13 October 2026

This NASDAQ China-Based Pharmaceutical Stock Slides Toward a Dime a Share

● At barely a dime a share, the stock sits firmly in penny-stock territory.

Nitish Kishor | 13 October 2026

This NASDAQ Small-Cap Biotech Stock Pulls Back in a Thin-Float Reversal

● No trial result, regulatory decision or financing has been tied to the move.

Nitish Kishor | 13 October 2026

Charles River Laboratories (NYSE:CRL) Draws Analyst Upgrades After Its Investor Day

Charles River Laboratories International, Inc. (NYSE:CRL) has a market capitalisation of about $14.4 billion. Following a September 24 Investor Day, several analysts raised targets, and UBS resumed coverage at Buy with a $357 target. Investors may be assessing whether the long-range targets are credible.

Nitish Kishor | 13 October 2026

CervoMed (NASDAQ:CRVO): A Data-Heavy Autumn as Neflamapimod Readouts Meet a Cash Runway to Q3 2027

CervoMed (NASDAQ:CRVO), a clinical-stage company developing neflamapimod for neurodegenerative conditions, has a crowded calendar of scientific events through the end of 2026. The International Society for Frontotemporal Dementia (ISFTD) conference ran from October 8 to 11, where the company planned to present 12-week biomarker …

Nitish Kishor | 13 October 2026

Contineum Therapeutics (NASDAQ:CTNM) Stock Tumbles as Healthcare Holds Firm

● The heaviest selling that day was in AI and semiconductor stocks, not healthcare.

Nitish Kishor | 13 October 2026

Bausch + Lomb (NYSE:BLCO) Stock Falls Even as Healthcare Draws Rotation Flows

● The chip selloff does not explain a drop in this eye-health company.

Nitish Kishor | 13 October 2026

Can Celularity (NASDAQ:CELU) Meet a November Nasdaq Filing Deadline While Pursuing a Recapitalization?

Celularity Inc. (NASDAQ:CELU), a regenerative and cellular medicine company based in New Jersey, has had a busy period of corporate announcements: a private placement as part of a planned recapitalization, new board appointments, manufacturing and wellness partnerships, and a Nasdaq notice over delayed quarterly …

Nitish Kishor | 13 October 2026
Support

Hi! How can we help you today?

Loading…